Literature DB >> 6190549

Histochemical characterization of different types of intestinal metaplasia in gastric mucosa.

D I Segura, C Montero.   

Abstract

The histochemical patterns of mucosubstances in 1.010 intestinal metaplasia (IM) foci in stomachs removed during surgery for benign ulcer and carcinoma has been studied. Two kinds of IM were characterized: the complete and the incomplete types, with the first one subdivided in Small intestine Type I, Small intestine Type II, and Colonic type, based on their similarity of mucosubstances, with those found in normal small intestine and colon, and the second one divided in two groups, depending on the presence or absence of sulfomucins. The incomplete type with sulfomucins was significantly more frequent in patients with carcinoma than in benign ulcer cases (P less than 0.001) as well as, in stomachs bearing intestinal type of carcinoma than in stomachs with diffuse type of carcinoma (P less than 0.005). The significance of the different types of IM, in relation to the gastric pathologic findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190549     DOI: 10.1002/1097-0142(19830801)52:3<498::aid-cncr2820520320>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia.

Authors:  Tetsuya Tsukamoto; Kenichi Inada; Harunari Tanaka; Tsutomu Mizoshita; Mami Mihara; Toshikazu Ushijima; Yoshitaka Yamamura; Shigeo Nakamura; Masae Tatematsu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-04       Impact factor: 4.553

2.  Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma.

Authors:  Tsutomu Namikawa; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

3.  Detection of sulfated glycoproteins in intestinal metaplasia: a comparison of traditional mucin staining with immunohistochemistry for the sulfo-Lewis(a) carbohydrate epitope.

Authors:  K Bodger; F Campbell; J M Rhodes
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

4.  The aberrant expression of Lewis a antigen in intestinal metaplastic cells of gastric mucosa is caused by augmentation of Lewis enzyme expression.

Authors:  Y Ikehara; S Nishihara; T Kudo; T Hiraga; K Morozumi; T Hattori; H Narimatsu
Journal:  Glycoconj J       Date:  1998-08       Impact factor: 2.916

5.  Is intestinal metaplasia a risk for gastric carcinoma?

Authors:  P Sossai; R Cielo; R Barbazza
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

6.  Expression of small intestinal and colonic phenotypes in complete intestinal metaplasia of the human stomach.

Authors:  Harunari Tanaka; Tetsuya Tsukamoto; Tsutomu Mizoshita; Ken-ichi Inada; Naotaka Ogasawara; Xueyuan Cao; Sosuke Kato; Takashi Joh; Masae Tatematsu
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

7.  Intestinal metaplasia in endoscopic biopsy specimens of gastric mucosa.

Authors:  G A Rothery; D W Day
Journal:  J Clin Pathol       Date:  1985-06       Impact factor: 3.411

8.  Subtypes of intestinal metaplasia and Helicobacter pylori.

Authors:  M E Craanen; P Blok; W Dekker; J Ferwerda; G N Tytgat
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

9.  Interobserver variation in histopathological assessment of Helicobacter pylori gastritis.

Authors:  Ozlem Aydin; Reyhan Egilmez; Tuba Karabacak; Arzu Kanik
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

10.  Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.

Authors:  M I Filipe; F Potet; W V Bogomoletz; P A Dawson; B Fabiani; P Chauveinc; A Fenzy; B Gazzard; D Goldfain; R Zeegen
Journal:  Gut       Date:  1985-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.